Company Description
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide.
The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services.
Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery.
It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands.
The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023.
Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 1937 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | Prahlad Singh |
Contact Details
Address: 77 4th Avenue Waltham, Massachusetts 02451 United States | |
| Phone | (781) 663-6900 |
| Website | revvity.com |
Stock Details
| Ticker Symbol | RVTY |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000031791 |
| CUSIP Number | 714046109 |
| ISIN Number | US7140461093 |
| Employer ID | 04-2052042 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Prahlad R. Singh Ph.D. | Chief Executive Officer, President and Director |
| Maxwell Krakowiak | Senior Vice President and Chief Financial Officer |
| Tajinder S. Vohra | Senior Vice President of Global Operations |
| Joel S. Goldberg | Senior Vice President of Administration, General Counsel and Secretary |
| Miriame Victor | Senior Vice President and Chief Commercial Officer |
| Bryan A. Kipp | Senior Vice President of Technology and Licensing |
| Madhuri Hegde FACMG, Ph.D. | Senior Vice President and Chief Scientific Officer |
| Stephen Barr Willoughby | Senior Vice President of Investor Relations and Head of ESG |
| Magali Four | Senior Vice President and Chief People and Culture Officer |
| Robert Francis Friel | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2025 | ARS | Filing |
| Mar 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 12, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 28, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 26, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | 144 | Filing |
| Jan 31, 2025 | 8-K | Current Report |